» Articles » PMID: 33962357

Pre-clinical Evaluation of ImmunoPET Imaging Using Agonist CD40 Monoclonal Antibody in Pancreatic Tumor-bearing Mice

Overview
Journal Nucl Med Biol
Publisher Elsevier
Date 2021 May 7
PMID 33962357
Citations 1
Authors
Affiliations
Soon will be listed here.
Abstract

Background: A novel [Cu]Cu-NOTA-aCD40 immunoPET tracer was developed to image a CD40 pancreatic tumor model in C57BL/6 mice and to study the biodistribution profile of the agonist CD40 (aCD40) monoclonal antibody (mAb) alone or combined with other mAbs.

Procedures: Copper-64 ([Cu]Cu) labeled NOTA-aCD40 and NOTA-IgG (10 μg; 7 MBq) were injected intravenously into C57BL/6 mice with subcutaneous mT4 tumors to assess specificity 48 h post injection (p.i.) through positron emission tomography/computed tomography (PET/CT) imaging and biodistribution studies (n = 5). [Cu]Cu-NOTA-aCD40 was injected alone or simultaneously in combination with a therapeutic mass of cold aCD40 (100 μg), aPD-1 (200 μg) and aCTLA-4 (200 μg) mAbs. A group of mice with or without tumor received the second round of injections 1 or 3 weeks apart, respectively. PET/CT imaging and biodistribution studies were performed at 48 h p.i. The organ dose for [Cu]Cu was estimated based on biodistribution studies with 2 μg [Cu]Cu-NOTA-aCD40 (corresponds to 5 mg patient dose) in non-tumor bearing mice.

Results: [Cu]Cu-NOTA-aCD40 accumulation was 2.3- and 7.8-fold higher than [Cu]Cu-NOTA-IgG in tumors and spleen, respectively, indicating the specificity of aCD40 mAb in a mouse pancreatic tumor model. Tumor accumulation of [Cu]Cu-NOTA-aCD40 was 21.2 ± 7.3%ID/g at 48 h after injection. Co-injection of [Cu]Cu-NOTA-aCD40 with cold aCD40 mAb alone or with PD-1 and CTLA-4 mAbs reduced both spleen and tumor uptake, whereas liver uptake was increased. With the second round of injections, the liver was the only organ with substantial uptake. With a 2 μg administered dose of [Cu]Cu-NOTA-aCD40 in a dosimetry study, the liver to spleen ratio was greater compared to the 10 μg dose (2.8 vs 0.37; respectively). The human equivalent for the highest dose organ (liver) was 198 ± 28.7 μSv/MBq.

Conclusions: A CD40-immunoreactive [Cu]Cu-NOTA-aCD40 probe was developed. The ratio of spleen to liver accumulation exceeded that of the IgG isotype and was greatest with a single small, injected mass. The safety of human patient imaging with [Cu]Cu was established based on extrapolation of the organ specificity to human imaging.

Citing Articles

Multiomic analysis for optimization of combined focal and immunotherapy protocols in murine pancreatic cancer.

Wang J, Fite B, Kare A, Wu B, Raie M, Tumbale S Theranostics. 2022; 12(18):7884-7902.

PMID: 36451859 PMC: 9706583. DOI: 10.7150/thno.73218.

References
1.
Lamberts L, Williams S, van Scheltinga A, Lub-de Hooge M, Schroder C, Gietema J . Antibody positron emission tomography imaging in anticancer drug development. J Clin Oncol. 2015; 33(13):1491-504. DOI: 10.1200/JCO.2014.57.8278. View

2.
Boj S, Hwang C, Baker L, Chio I, Engle D, Corbo V . Organoid models of human and mouse ductal pancreatic cancer. Cell. 2015; 160(1-2):324-38. PMC: 4334572. DOI: 10.1016/j.cell.2014.12.021. View

3.
Herbst R, Soria J, Kowanetz M, Fine G, Hamid O, Gordon M . Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients. Nature. 2014; 515(7528):563-7. PMC: 4836193. DOI: 10.1038/nature14011. View

4.
Borjesson P, Jauw Y, de Bree R, Roos J, Castelijns J, Leemans C . Radiation dosimetry of 89Zr-labeled chimeric monoclonal antibody U36 as used for immuno-PET in head and neck cancer patients. J Nucl Med. 2009; 50(11):1828-36. DOI: 10.2967/jnumed.109.065862. View

5.
Hoves S, Ooi C, Wolter C, Sade H, Bissinger S, Schmittnaegel M . Rapid activation of tumor-associated macrophages boosts preexisting tumor immunity. J Exp Med. 2018; 215(3):859-876. PMC: 5839760. DOI: 10.1084/jem.20171440. View